Microbot Medical Stock Shoots Higher: Here's Why

Microbot Medical Inc MBOT announced an extended joint preclinical animal study at a European-based research lab.

A team of six European interventional radiologists utilized the system and performed a total of 48 catheterizations to pre-determined vascular targets, including distal branches of hepatic, gastric, splenic, mesenteric, renal, and hypogastric arteries, with a 100% success rate of reaching the intended target.

Based on real-time user feedback, the interventional radiologists found the system intuitive and easy to set up and use and were impressed with the ability to control procedures remotely via the LIBERTY Robotic System's remote controller.

The company plans on performing preclinical studies in the U.S. and other target markets, as well as the first-in-human case in markets outside the U.S., in preparation for the continued progression toward commercialization of the LIBERTY Surgical Robotic System.

The 48 successful catheterizations are part of the company's recent announcement regarding surpassing the 100th catheterization during multiple preclinical studies, with a 95% success rate of reaching pre-determined vascular targets.

Price Action: MOBT shares are up 146.3% at $3.03 on the last check Monday.